Intrinsiqq
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc.

FLNA

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$32M
EPS-$0.87
P/E-0.74
P/FCF-1.13
EV/EBITDA0.33
FCF Yield–
Div. Yield–
Net Debt/FCF1.6x
Filana Therapeutics, Inc. intrinsic value
52-Week Range
$0.43$1.91

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$42M

▼ -273.7% YoY

Op. Margin

–

ROIC

-54.30%

▲ +10.4pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$29M

▲ +71.9% YoY

Op. Cash Flow (TTM)

-$29M

▲ +72.4% YoY

Net Debt

-$47M

Net Cash Position

Cash & Equiv.

$47M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with FLNA

CompareIntrinsic value
EQEquillium, Inc.
$1.06-5.36%40
ROIVRoivant Sciences Ltd
$38.66-0.78%42
NERVMinerva Neurosciences Inc.
$2.00-5.66%10
KROSKeros Therapeutics Inc.
$11.08-2.72%20
CRNXCrinetics Pharmaceuticals Inc.
No recent price40
ENVBEnveric Biosciences Inc.
$1.35-4.26%21
PVLAPavella Therapeutics Inc.
$143.21-1.76%40
TNXPTonix Pharmaceuticals Holding Corp
$2.38-6.67%40

Held by ETFs

FLNA is in 2 US ETFs. The largest of them, with FLNA's weight in each:

Filana Therapeutics (FLNA) in three numbers

Quality score
40/100
Best check: revenue growth, 34.7%. Weakest: return on capital, -54.3%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.74
Negative: a loss over the last twelve months. Price to free cash flow -1.13.
Financials

Questions about Filana Therapeutics

Is Filana Therapeutics a high-quality business?

Filana Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 34.7%, and its weakest is return on capital at -54.3%. The Quality tab shows every check against its target.

Does Filana Therapeutics (FLNA) pay a dividend?

No. Filana Therapeutics (FLNA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in FLNA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FLNA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.